Trihexyphenidyl

Trihexyphenidyl is a selective M1-preferring muscarinic acetylcholine receptor antagonist used clinically to reduce the tremor and rigidity of Parkinson disease and to manage extrapyramidal symptoms, such as dystonia and parkinsonism, caused by antipsychotic medications. By blocking central cholinergic tone it helps rebalance the dopamine and acetylcholine relationship in the basal ganglia, which underlies its antiparkinsonian effect.

Unlike the cholinergic compounds commonly grouped as nootropics, trihexyphenidyl works in the opposite pharmacological direction, suppressing acetylcholine signaling. Because central cholinergic transmission supports memory and attention, anticholinergics of this type typically impair cognition, cause confusion, and in older adults are associated with delirium and heightened long-term cognitive risk; it therefore has no legitimate cognitive-enhancement role.

At doses above the therapeutic range trihexyphenidyl becomes a deliriant, producing euphoria, agitation, and vivid hallucinations along with the classic antimuscarinic toxidrome of dry mouth, blurred vision, urinary retention, rapid heartbeat, elevated body temperature, and, in overdose, seizures and dangerous delirium. It has a recognized potential for misuse and dependence, and abrupt discontinuation after prolonged use can provoke withdrawal. The entry lists it as a serious drug precisely to signal that it is a prescription medication with meaningful hazards rather than a benign supplement.

High doses cause a dangerous anticholinergic syndrome with overheating, racing heart, urinary retention, agitation and delirium; the state is usually distressing rather than enjoyable. It adds to the total anticholinergic burden when combined with antihistamines, tricyclic antidepressants or other anticholinergics, and that stacking raises the risk of overheating, seizures and cardiac problems. Long-term anticholinergic exposure is also linked to cognitive impairment. Not medical advice.

Trihexyphenidyl is a muscarinic antagonist, and its interactions are almost entirely a matter of cumulative anticholinergic load. Adding it to tricyclic antidepressants, first-generation antihistamines, oxybutynin, low-potency antipsychotics such as chlorpromazine, or clozapine produces additive dry mouth, blurred vision, urinary retention and constipation, and at higher burden confusion, hallucination, hyperthermia from impaired sweating, and paralytic ileus. Older adults are the most vulnerable, and anticholinergic delirium is regularly mistaken for a worsening of the underlying illness.

With levodopa the interaction is mechanical: delayed gastric emptying leaves levodopa longer in the stomach to be degraded, and peak serum concentrations fall by roughly 16 to 20 percent. Involuntary movements can also increase when the two run together.

Alongside antipsychotics, anticholinergics can unmask or aggravate tardive dyskinesia even while relieving parkinsonian side effects. They also oppose cholinesterase inhibitors such as donepezil directly, and they blunt the prokinetic action of metoclopramide.

Checking a whole stack? Run it through interactions + stacks.

Trihexyphenidyl, marketed as Artane and also known as benzhexol, is a synthetic antimuscarinic agent introduced by Lederle Laboratories and approved in the United States in 1949 for the treatment of Parkinson disease. It was among the earliest anticholinergic antiparkinsonian drugs, developed in the era before levodopa to counter tremor and rigidity, and it remains indicated for symptomatic Parkinson disease and for drug-induced extrapyramidal (movement) side effects.

In legitimate medicine trihexyphenidyl has a settled reputation as a useful but second-line anticholinergic for tremor and drug-induced movement disorders, valued yet used cautiously because of its cognitive and peripheral antimuscarinic burden. Beyond the clinic it carries a very different and cautionary reputation as a deliriant of abuse: at supratherapeutic doses it produces euphoria, stimulation, and hallucinations, and reports ranging from the neurologist Oliver Sacks to soldiers in conflict zones document recreational misuse. It is emphatically not a nootropic and is flagged as a serious drug.